A phase 2 clinical trial of adjuvant ado-trastuzumab emtansine (T-DM1) for patients with HER2-positive salivary gland cancer.

Authors: Glenn J. Hanna, Ruichao Shi, Jay Justin Liao, Alexander T. Pearson, Ari Joseph Rosenberg, Alan Loh Ho, Eleni M. Rettig, Roy B. Tishler, Rosh K. Sethi, Donald J. Annino, Laura A Goguen, Kartik Sehgal, Michael J. Dennis, Vickie Y. Jo, Kristine S. Wong, Conor Ernst Steuer, Ravindra Uppaluri, Jonathan Daniel Schoenfeld, Robert I. Haddad, Danielle N Margalit

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps6124

Source: Full article


Abstract

TPS6124